This is in line with previous reports showing that downmodulation of JAK1 and JAK2, both essential tyrosine kinases in the IFNγ-signaling pathway, in tumor cells results in resistance to CD3 bsAbs (Arenas et al, 2021; Liu et al, 2021). Here, JAK2 is linked to neoplasm.